{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:49:52Z","timestamp":1789206592522,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.ejca.2009.05.012","type":"journal-article","created":{"date-parts":[[2009,6,2]],"date-time":"2009-06-02T04:13:07Z","timestamp":1243915987000},"page":"3064-3073","source":"Crossref","is-referenced-by-count":11,"title":["The influence of menopausal hormone therapy on tumour characteristics and survival in endometrial cancer patients"],"prefix":"10.1016","volume":"45","author":[{"given":"Chantal C.","family":"Org\u00e9as","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Wedr\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Dickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Czene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2009.05.012_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0029-7844(97)00577-2","article-title":"Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens","volume":"91","author":"Cushing","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejca.2009.05.012_bib2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/0029-7844(94)00383-O","article-title":"Hormone replacement therapy and endometrial cancer risk: a meta-analysis","volume":"85","author":"Grady","year":"1995","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejca.2009.05.012_bib3","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1158\/1055-9965.EPI-05-0111","article-title":"Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women","volume":"14","author":"Lacey","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejca.2009.05.012_bib4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1008909128110","article-title":"Risks of breast and endometrial cancer after estrogen and estrogen\u2013progestin replacement","volume":"10","author":"Persson","year":"1999","journal-title":"Cancer Cause Control"},{"key":"10.1016\/j.ejca.2009.05.012_bib5","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/S0140-6736(98)10233-7","article-title":"Low-potency oestrogen and risk of endometrial cancer: a case-control study","volume":"353","author":"Weiderpass","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2009.05.012_bib6","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(05)66455-0","article-title":"Endometrial cancer and hormone-replacement therapy in the Million Women Study","volume":"365","author":"Beral","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2009.05.012_bib7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0140-6736(96)07365-5","article-title":"Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women","volume":"349","author":"Beresford","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2009.05.012_bib8","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/jnci\/89.15.1110","article-title":"Estrogen\u2013progestin replacement therapy and endometrial cancer","volume":"89","author":"Pike","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2009.05.012_bib9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/jnci\/91.13.1131","article-title":"Risk of endometrial cancer following estrogen replacement with and without progestins","volume":"91","author":"Weiderpass","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2009.05.012_bib10","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/cncr.22525","article-title":"Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort","volume":"109","author":"Lacey","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2009.05.012_bib11","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/j.1471-0528.2000.tb11654.x","article-title":"The endometrial response to sequential and continuous combined oestrogen\u2013progestogen replacement therapy","volume":"107","author":"Sturdee","year":"2000","journal-title":"BJOG"},{"key":"10.1016\/j.ejca.2009.05.012_bib12","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/jama.290.13.1739","article-title":"Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women\u2019s Health Initiative randomized trial","volume":"290","author":"Anderson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2009.05.012_bib13","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0002-9378(96)70027-3","article-title":"Estrogen replacement in surgical stages I and II endometrial cancer survivors","volume":"175","author":"Chapman","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejca.2009.05.012_bib14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0140-6736(80)92115-7","article-title":"Oestrogen use and survival in endometrial cancer","volume":"2","author":"Collins","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2009.05.012_bib15","first-page":"260","article-title":"Risk of endometrial cancer mortality by ever-use of sex hormones and other factors in Japan","volume":"7","author":"Khan","year":"2006","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ejca.2009.05.012_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/gyno.1993.1107","article-title":"Endometrial adenocarcinoma involving adenomyosis without true myometrial invasion is characterized by frequent preceding estrogen therapy, low histologic grades, and excellent prognosis","volume":"49","author":"Mittal","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2009.05.012_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1006\/gyno.1993.1112","article-title":"Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment: comparison of clinical and histopathological characteristics","volume":"49","author":"Nyholm","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2009.05.012_bib18","first-page":"269","article-title":"Changing trends and prognostic features in endometrial cancer associated with exogenous estrogen therapy","volume":"54","author":"Robboy","year":"1979","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejca.2009.05.012_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00001648-199701000-00010","article-title":"Cause-specific mortality in women receiving hormone replacement therapy","volume":"8","author":"Schairer","year":"1997","journal-title":"Epidemiology"},{"key":"10.1016\/j.ejca.2009.05.012_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00001648-199801000-00020","article-title":"Menopausal hormone use and endometrial cancer, by tumor grade and invasion","volume":"9","author":"Shapiro","year":"1998","journal-title":"Epidemiology"},{"key":"10.1016\/j.ejca.2009.05.012_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000299600","article-title":"Endometrial carcinoma: histopathology, survival, and exogenous estrogens","volume":"12","author":"Smith","year":"1981","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.ejca.2009.05.012_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1008945721786","article-title":"Use of oral contraceptives and endometrial cancer risk (Sweden)","volume":"10","author":"Weiderpass","year":"1999","journal-title":"Cancer Cause Control"},{"key":"10.1016\/j.ejca.2009.05.012_bib23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1023\/A:1008919717930","article-title":"Physical activity and postmenopausal endometrial cancer risk (Sweden)","volume":"11","author":"Moradi","year":"2000","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ejca.2009.05.012_bib24","first-page":"487","article-title":"Organochlorines and endometrial cancer risk","volume":"9","author":"Weiderpass","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejca.2009.05.012_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1023\/A:1008946825313","article-title":"Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden)","volume":"11","author":"Weiderpass","year":"2000","journal-title":"Cancer Cause Control"},{"key":"10.1016\/j.ejca.2009.05.012_bib26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/carcin\/21.4.623","article-title":"Estrogen receptor alpha gene polymorphisms and endometrial cancer risk","volume":"21","author":"Weiderpass","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejca.2009.05.012_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2307\/2336391","article-title":"Calculation of polychotomous logistic regression parameters using individualized regressions","volume":"71","author":"Begg","year":"1984","journal-title":"Biometrika"},{"key":"10.1016\/j.ejca.2009.05.012_bib28","first-page":"101","article-title":"The relative survival rate: a statistical methodology","volume":"6","author":"Ederer","year":"1961","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ejca.2009.05.012_bib29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.0.CO;2-T","article-title":"Cancer incidence and mortality in women receiving estrogen and estrogen\u2013progestin replacement therapy \u2013 long-term follow-up of a Swedish cohort","volume":"67","author":"Persson","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2009.05.012_bib30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0029-7844(00)01221-7","article-title":"Estrogen replacement therapy in endometrial cancer patients: a matched control study","volume":"97","author":"Suriano","year":"2001","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejca.2009.05.012_bib31","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(07)70245-0","article-title":"Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995\u201399: results of the EUROCARE-4 study","volume":"8","author":"Berrino","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2009.05.012_bib32","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMsa0707519","article-title":"Socioeconomic inequalities in health in 22 European countries","volume":"358","author":"Mackenbach","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2009.05.012_bib33","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/eurpub\/ckn022","article-title":"Patient survival for all cancers combined as indicator of cancer control in Europe","volume":"18","author":"Verdecchia","year":"2008","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.ejca.2009.05.012_bib34","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ejca.2007.12.015","article-title":"Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s","volume":"44","author":"Karim-Kos","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2009.05.012_bib35","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/humupd\/dmi028","article-title":"Breast cancer risk with postmenopausal hormonal treatment","volume":"11","author":"Collins","year":"2005","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ejca.2009.05.012_bib36","first-page":"1175","article-title":"Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50\u201364years","volume":"12","author":"Daling","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejca.2009.05.012_bib37","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1001\/jama.281.22.2091","article-title":"Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women\u2019s Health Study","volume":"281","author":"Gapstur","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2009.05.012_bib38","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/bcr2145","article-title":"Menopausal hormone therapy in relation to breast cancer characteristics, prognosis: a cohort study","volume":"10","author":"Rosenberg","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2009.05.012_bib39","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1002\/ijc.22218","article-title":"Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival","volume":"119","author":"Mascarenhas","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2009.05.012_bib40","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(07)60534-0","article-title":"Ovarian cancer and hormone replacement therapy in the Million Women Study","volume":"369","author":"Beral","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2009.05.012_bib41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909003505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909003505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T01:22:16Z","timestamp":1545182536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804909003505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":41,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0959804909003505"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2009.05.012","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}